

# Florian S Gutzwiller

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1319109/publications.pdf>

Version: 2024-02-01

37  
papers

1,097  
citations

471061

17  
h-index

414034

32  
g-index

42  
all docs

42  
docs citations

42  
times ranked

1644  
citing authors

#	ARTICLE	IF	CITATIONS
1	FERGlor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2011, 141, 846-853.e2.	0.6	304
2	In-hospital Delay Increases the Risk of Perforation in Adults with Appendicitis. <i>World Journal of Surgery</i> , 2011, 35, 1626-1633.	0.8	102
3	Factors associated with appropriate inhaler use in patients with COPD &ndash; lessons from the REAL survey. <i>International Journal of COPD</i> , 2018, Volume 13, 695-702.	0.9	63
4	Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR&#x2013;HF trial: an analysis for the UK. <i>European Journal of Heart Failure</i> , 2012, 14, 782-790.	2.9	50
5	Early morning melatonin administration impairs psychomotor vigilance. <i>Behavioural Brain Research</i> , 2001, 121, 167-172.	1.2	46
6	Economic burden of COPD in a Swedish cohort: the ARCTIC study. <i>International Journal of COPD</i> , 2018, Volume 13, 275-285.	0.9	43
7	Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients. <i>Npj Primary Care Respiratory Medicine</i> , 2018, 28, 33.	1.1	38
8	Gender differences among Swedish COPD patients: results from the ARCTIC, a real-world retrospective cohort study. <i>Npj Primary Care Respiratory Medicine</i> , 2019, 29, 45.	1.1	38
9	Patients' perspectives on COPD: findings from a social media listening study. <i>ERJ Open Research</i> , 2019, 5, 00128-2018.	1.1	37
10	Evaluation of exacerbations and blood eosinophils in UK and US COPD populations. <i>Respiratory Research</i> , 2019, 20, 178.	1.4	34
11	&lt;p&gt;Impact of COPD diagnosis timing on clinical and economic outcomes: the ARCTIC observational cohort study&lt;/p&gt;. <i>International Journal of COPD</i> , 2019, Volume 14, 995-1008.	0.9	33
12	End-of-life costs of medical care for advanced stage cancer patients. <i>Vojnosanitetski Pregled</i> , 2015, 72, 334-341.	0.1	31
13	Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis. <i>International Journal of Cardiology</i> , 2013, 168, 3878-3883.	0.8	30
14	Identifying the associated risks of pneumonia in COPD patients: ARCTIC an observational study. <i>Respiratory Research</i> , 2018, 19, 172.	1.4	28
15	Do citizens have minimum medical knowledge? A survey. <i>BMC Medicine</i> , 2007, 5, 14.	2.3	26
16	Osteoporosis and fracture risk associated with inhaled corticosteroid use among Swedish COPD patients: the ARCTIC study. <i>European Respiratory Journal</i> , 2021, 57, 2000515.	3.1	21
17	Differences in COPD Exacerbation Risk Between Women and Men. <i>Chest</i> , 2019, 156, 674-684.	0.4	19
18	&lt;p&gt;Patient-Reported Outcomes (PROs) in COPD Clinical Trials: Trends and Gaps&lt;/p&gt;. <i>International Journal of COPD</i> , 2020, Volume 15, 1789-1800.	0.9	17

#	ARTICLE	IF	CITATIONS
19	A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 846-851.	0.4	15
20	Gathering Structured Patient Insight to Drive the PRO Strategy in COPD: Patient-Centric Drug Development from Theory to Practice. <i>Advances in Therapy</i> , 2020, 37, 17-26.	1.3	15
21	<p>Impact of cough and mucus on COPD patients: primary insights from an exploratory study with an Online Patient Community</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 1365-1376.	0.9	14
22	<p>Clinical Impact and Healthcare Resource Utilization Associated with Early versus Late COPD Diagnosis in Patients from UK CPRD Database</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 1729-1738.	0.9	11
23	Cost Effectiveness of Sucoferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland. <i>Pharmacoeconomics</i> , 2015, 33, 1311-1324.	1.7	9
24	The Impact of Exacerbation Frequency on Clinical and Economic Outcomes in Swedish COPD Patients: The ARCTIC Study. <i>International Journal of COPD</i> , 2021, Volume 16, 701-713.	0.9	9
25	A questionnaire on treatment satisfaction and disease specific knowledge among patients with acute coronary syndrome. II: Insights for patient education and quality improvement. <i>Patient Education and Counseling</i> , 2012, 86, 366-371.	1.0	7
26	Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 43-51.	2.5	6
27	Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population. <i>Respiratory Research</i> , 2017, 18, 206.	1.4	5
28	Inhaled corticosteroids and the risk of type 2 diabetes among Swedish COPD patients. <i>Npj Primary Care Respiratory Medicine</i> , 2020, 30, 47.	1.1	5
29	A questionnaire on treatment satisfaction and disease specific knowledge among patients with acute coronary syndrome. I: Are treatment satisfaction and disease specific knowledge continuous latent traits?. <i>Patient Education and Counseling</i> , 2012, 86, 360-365.	1.0	3
30	&lt;p&gt;Is the St. George&acircm;s Respiratory Questionnaire an Appropriate Measure of Symptom Severity and Activity Limitations for Clinical Trials in COPD? Analysis of Pooled Data from Five Randomized Clinical Trials&lt;/p&gt;. <i>International Journal of COPD</i> , 2020, Volume 15, 2103-2113.	0.9	3
31	People living with moderate-to-severe COPD prefer improvement of daily symptoms over the improvement of exacerbations: a multicountry patient preference study. <i>ERJ Open Research</i> , 2022, 8, 00686-2021.	1.1	3
32	<p>Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 787-797.	0.9	1
33	Social Media Use in COPD Patients in Germany and Switzerland. <i>Pneumologie</i> , 2021, 75, 583-591.	0.1	1
34	Treatment Patterns, Socioeconomic Status and Clinical Burden in Mild COPD: A Swedish Real-World, Retrospective Cohort Study, the ARCTIC Study. <i>International Journal of COPD</i> , 0, Volume 17, 1409-1421.	0.9	1
35	Indacaterol/glycopyrronium (IND/GLY) is cost-effective compared with salmeterol/fluticasone (SFC) in Swedish chronic obstructive pulmonary disease (COPD) patients. , 2017, , .		0
36	Estimating the number of patients&acircm needed to treat (NNT) with indacaterol/glycopyrronium to prevent COPD exacerbations: Results from the FLAME study. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
37	Gender and economic aspects of COPD in a Swedish cohort: The ARCTIC study. , 2017, , .		0